JP2006503819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503819A5 JP2006503819A5 JP2004531921A JP2004531921A JP2006503819A5 JP 2006503819 A5 JP2006503819 A5 JP 2006503819A5 JP 2004531921 A JP2004531921 A JP 2004531921A JP 2004531921 A JP2004531921 A JP 2004531921A JP 2006503819 A5 JP2006503819 A5 JP 2006503819A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxycholesterol
- group
- mammalian
- cells
- oxysterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MCKLJFJEQRYRQT-APGJSSKUSA-N 20-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@](C)(O)CCCC(C)C)[C@@]1(C)CC2 MCKLJFJEQRYRQT-APGJSSKUSA-N 0.000 claims 12
- RZPAXNJLEKLXNO-UHFFFAOYSA-N (20R,22R)-3beta,22-Dihydroxylcholest-5-en Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C(O)CCC(C)C)C1(C)CC2 RZPAXNJLEKLXNO-UHFFFAOYSA-N 0.000 claims 10
- RZPAXNJLEKLXNO-QUOSNDFLSA-N (22S)-22-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)[C@@H](O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-QUOSNDFLSA-N 0.000 claims 10
- RZPAXNJLEKLXNO-GFKLAVDKSA-N (22R)-22-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)[C@H](O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-GFKLAVDKSA-N 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims 8
- 239000007943 implant Substances 0.000 claims 8
- 229960000249 pregnenolone Drugs 0.000 claims 8
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- INBGSXNNRGWLJU-ZHHJOTBYSA-N 25-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 INBGSXNNRGWLJU-ZHHJOTBYSA-N 0.000 claims 5
- INBGSXNNRGWLJU-UHFFFAOYSA-N 25epsilon-Hydroxycholesterin Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(CCCC(C)(C)O)C)C1(C)CC2 INBGSXNNRGWLJU-UHFFFAOYSA-N 0.000 claims 5
- 210000004962 mammalian cell Anatomy 0.000 claims 5
- 239000012190 activator Substances 0.000 claims 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 2
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims 2
- 102000015439 Phospholipases Human genes 0.000 claims 2
- 108010064785 Phospholipases Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 229940114079 arachidonic acid Drugs 0.000 claims 2
- 235000021342 arachidonic acid Nutrition 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003248 enzyme activator Substances 0.000 claims 2
- 230000001582 osteoblastic effect Effects 0.000 claims 2
- 230000002188 osteogenic effect Effects 0.000 claims 2
- 239000000199 parathyroid hormone Substances 0.000 claims 2
- 229960001319 parathyroid hormone Drugs 0.000 claims 2
- 229940127293 prostanoid Drugs 0.000 claims 2
- 150000003814 prostanoids Chemical class 0.000 claims 2
- 235000013024 sodium fluoride Nutrition 0.000 claims 2
- 239000011775 sodium fluoride Substances 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- IXRAQYMAEVFORF-UTLNTRLCSA-N (3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IXRAQYMAEVFORF-UTLNTRLCSA-N 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 230000003185 calcium uptake Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 230000004072 osteoblast differentiation Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40671502P | 2002-08-29 | 2002-08-29 | |
| PCT/US2003/027105 WO2004019884A2 (en) | 2002-08-29 | 2003-08-28 | Agents and methods for enhancing bone formation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503819A JP2006503819A (ja) | 2006-02-02 |
| JP2006503819A5 true JP2006503819A5 (enExample) | 2006-10-19 |
Family
ID=31978345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004531921A Pending JP2006503819A (ja) | 2002-08-29 | 2003-08-28 | 骨形成を増進するための作用剤および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7897588B2 (enExample) |
| EP (1) | EP1556057A4 (enExample) |
| JP (1) | JP2006503819A (enExample) |
| AU (1) | AU2003268260B2 (enExample) |
| CA (1) | CA2495882A1 (enExample) |
| WO (1) | WO2004019884A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2495882A1 (en) | 2002-08-29 | 2004-03-11 | The Regents Of The University Of California | Agents and methods for enhancing bone formation |
| CA2529558A1 (en) * | 2003-07-01 | 2005-01-13 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
| US7318925B2 (en) | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| JP2007521232A (ja) | 2003-08-08 | 2007-08-02 | アブジェニックス・インコーポレーテッド | 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用 |
| WO2005020928A2 (en) * | 2003-08-29 | 2005-03-10 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| US8193312B2 (en) | 2004-01-28 | 2012-06-05 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
| US8188219B2 (en) * | 2004-01-28 | 2012-05-29 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
| US8415302B2 (en) | 2004-01-28 | 2013-04-09 | The Regents Of The University Of California | Surgical applications for BMP binding protein |
| MXPA06014576A (es) * | 2004-06-24 | 2007-03-23 | Galapagos Nv | Agonistas de lxr para promover homeostasis osea. |
| US8753660B2 (en) * | 2004-11-29 | 2014-06-17 | The Regents Of The University Of California | Activating extraction of demineralized bone matrix |
| US20090202660A1 (en) * | 2005-04-07 | 2009-08-13 | The Regents Of The University Of California | Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation |
| ATE422028T1 (de) * | 2005-04-23 | 2009-02-15 | Ixetic Mac Gmbh | Axialkolbenmaschine |
| AU2006284650A1 (en) * | 2005-09-02 | 2007-03-08 | The Regents Of The University Of California | Osteogenic and anti-adipogenic oxysterols |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| WO2008011071A2 (en) * | 2006-07-19 | 2008-01-24 | The Regents Of The University Of California | Interactions of hedgehog and liver x receptor signaling pathways |
| WO2008082520A2 (en) | 2006-12-19 | 2008-07-10 | The Regents Of The University Of California | Inhibition of ppar gamma expression by specific osteogenic oxysterols |
| EP2146724A2 (en) * | 2007-03-16 | 2010-01-27 | The Regent of the University of California | Role of hedgehog signaling in atherosclerosis and cardiovascular disease |
| US8574567B2 (en) | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| WO2008137115A1 (en) | 2007-05-03 | 2008-11-13 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| JP2011505357A (ja) | 2007-12-03 | 2011-02-24 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール |
| MX371080B (es) | 2009-06-23 | 2020-01-15 | Univ California | Aumento de retención de bmp. |
| US9707318B2 (en) * | 2009-10-29 | 2017-07-18 | Shaker A. Mousa | Compositions of novel bone patch in bone and vascular regeneration |
| US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
| RU2632191C2 (ru) | 2012-05-07 | 2017-10-03 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез |
| AU2014259672A1 (en) | 2013-05-02 | 2015-12-03 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
| EP3229809B1 (en) | 2014-12-09 | 2019-11-27 | Warsaw Orthopedic, Inc. | Compounds and methods involving sterols |
| US9877836B2 (en) | 2015-07-10 | 2018-01-30 | Warsaw Orthopedic, Inc. | Compression resistant implants including an oxysterol and methods of use |
| US10632230B2 (en) | 2015-07-10 | 2020-04-28 | Warsaw Orthopedic, Inc. | Implants having a high drug load of an oxysterol and methods of use |
| US9987289B2 (en) | 2015-07-10 | 2018-06-05 | Warsaw Orthopedic, Inc. | Slow release oxysterols and methods of use |
| US9878070B2 (en) | 2015-06-17 | 2018-01-30 | Warsaw Orthopedic, Inc. | Malleable implants including an oxysterol and methods of use |
| US12171909B2 (en) | 2015-07-10 | 2024-12-24 | Warsaw Orthopedic, Inc. | Implants having a drug load of an oxysterol and methods of use |
| US9637514B1 (en) | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
| US10688222B2 (en) | 2016-11-21 | 2020-06-23 | Warsaw Orthopedic, Inc. | Lyophilized moldable implants containing an oxysterol |
| US11384114B2 (en) | 2016-12-09 | 2022-07-12 | Warsaw Orthopedic, Inc. | Polymorphic forms of an oxysterol and methods of making them |
| US10434106B2 (en) | 2017-05-19 | 2019-10-08 | Warsaw Orthopedic, Inc. | Oxysterol-statin compounds for bone growth |
| KR102081230B1 (ko) * | 2017-06-01 | 2020-02-25 | 연세대학교 산학협력단 | 골 관련 질환의 예방 또는 치료를 위한 약학 조성물 |
| US11464888B2 (en) | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
| CN110917397A (zh) * | 2018-09-20 | 2020-03-27 | 天津大学 | 基于病毒载体投递MicroRNA与骨粉的复合材料及其制备方法 |
| CN114507638B (zh) * | 2021-12-31 | 2024-01-02 | 浙江大学 | 一种抑制间充质干细胞衰老的优化培养基及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3887545A (en) * | 1973-11-12 | 1975-06-03 | Hoffmann La Roche | Synthesis of 1{60 -hydroxylated cholesterol derivatives |
| US4183852A (en) * | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| CA2160930A1 (en) * | 1995-10-19 | 1997-04-20 | Lloyd Cuttress | Pet feeder |
| CA2250874A1 (en) * | 1996-04-09 | 1997-10-16 | Btg International Limited | Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders |
| ES2329953T3 (es) * | 1996-04-19 | 2009-12-02 | Osiris Therapeutics, Inc. | Regeneracion e incremento de hueso utilizando celulas madre mesenquimales. |
| US6893830B1 (en) | 1996-09-27 | 2005-05-17 | The Board Of Regents Of The University Of Texas System | Method of screening oxysterol activation of LXRα |
| US6080779A (en) | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
| US5855920A (en) | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| HUP0001938A3 (en) | 1997-01-24 | 2001-09-28 | Univ California | Use of fxr, pparalpha and lxralpha activators for producing pharmaceutical compositions useful for restoring barrier function, promoting epidermal differentiation and inhibiting proliferation |
| US5929062A (en) | 1997-06-19 | 1999-07-27 | University Of Western Ontario | Oxysterol inhibition of dietary cholesterol uptake |
| AU8173098A (en) | 1997-06-27 | 1999-01-19 | Ontogeny, Inc. | Neuroprotective methods and reagents |
| US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| WO1999045923A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
| EP0943332A1 (en) * | 1998-03-19 | 1999-09-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Prevention and treatment of adhesions |
| US6316503B1 (en) * | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| US6586189B2 (en) | 1999-06-18 | 2003-07-01 | City Of Hope | Screening method for PPAR-γ ligands |
| WO2001015676A2 (en) | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US20020161026A1 (en) * | 2000-11-07 | 2002-10-31 | Paralkar Vishwas M. | Combination therapies for the stimulation of bone growth |
| AU2002247847A1 (en) | 2001-04-09 | 2002-10-21 | Lorantis Limited | Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| CA2495882A1 (en) | 2002-08-29 | 2004-03-11 | The Regents Of The University Of California | Agents and methods for enhancing bone formation |
| WO2005028616A2 (en) | 2003-07-24 | 2005-03-31 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Morphogen compositions and methods of use thereof to treat heart disorders |
| WO2005019264A2 (en) | 2003-08-18 | 2005-03-03 | Wyeth | Human lxr alpha variants |
| WO2005020928A2 (en) | 2003-08-29 | 2005-03-10 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| CA2575878A1 (en) | 2004-08-02 | 2006-02-09 | Novozymes A/S | Creation of diversity in polypeptides |
| US20090202660A1 (en) | 2005-04-07 | 2009-08-13 | The Regents Of The University Of California | Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation |
| AU2006284650A1 (en) | 2005-09-02 | 2007-03-08 | The Regents Of The University Of California | Osteogenic and anti-adipogenic oxysterols |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| EP2146724A2 (en) | 2007-03-16 | 2010-01-27 | The Regent of the University of California | Role of hedgehog signaling in atherosclerosis and cardiovascular disease |
-
2003
- 2003-08-28 CA CA002495882A patent/CA2495882A1/en not_active Abandoned
- 2003-08-28 US US10/524,945 patent/US7897588B2/en not_active Expired - Lifetime
- 2003-08-28 AU AU2003268260A patent/AU2003268260B2/en not_active Ceased
- 2003-08-28 EP EP03749213A patent/EP1556057A4/en not_active Withdrawn
- 2003-08-28 JP JP2004531921A patent/JP2006503819A/ja active Pending
- 2003-08-28 WO PCT/US2003/027105 patent/WO2004019884A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503819A5 (enExample) | ||
| Rutten et al. | Low-intensity pulsed ultrasound increases bone volume, osteoid thickness and mineral apposition rate in the area of fracture healing in patients with a delayed union of the osteotomized fibula | |
| Matsumoto et al. | Pulsed electromagnetic fields promote bone formation around dental implants inserted into the femur of rabbits | |
| JP2009512422A5 (enExample) | ||
| Cheng et al. | Calcium plasma implanted titanium surface with hierarchical microstructure for improving the bone formation | |
| Chien et al. | Poly (dopamine)-assisted immobilization of Arg-Gly-Asp peptides, hydroxyapatite, and bone morphogenic protein-2 on titanium to improve the osteogenesis of bone marrow stem cells | |
| JP2015517493A5 (enExample) | ||
| AU2003268260B2 (en) | Agents and methods for enhancing bone formation | |
| Park et al. | Effect of 980-nm GaAlAs diode laser irradiation on healing of extraction sockets in streptozotocin-induced diabetic rats: a pilot study | |
| Lin et al. | Strontium‐incorporated titanium implant surface treated by hydrothermal reactions promotes early bone osseointegration in osteoporotic rabbits | |
| CA2643732A1 (en) | Oxysterol compounds and the hedgehog pathway | |
| RU2014149153A (ru) | Новый аналог оксистерола, oxy149, индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез | |
| JP2015518493A5 (enExample) | ||
| Karlsson et al. | Atomically resolved tissue integration | |
| Chauhan et al. | Efficacy of simvastatin in bone regeneration after surgical removal of mandibular third molars: A clinical pilot study | |
| Chen et al. | Low-magnitude, high-frequency vibration promotes the adhesion and the osteogenic differentiation of bone marrow-derived mesenchymal stem cells cultured on a hydroxyapatite-coated surface: The direct role of Wnt/β-catenin signaling pathway activation | |
| RU2014149164A (ru) | Аналог оксистерола oxy133 индуцирует остеогенез и сигнальный путь hedgehog и ингибирует липогенез | |
| US9532994B2 (en) | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins | |
| Yamawaki et al. | RETRACTED: Effects of glucose concentration on osteogenic differentiation of type II diabetes mellitus rat bone marrow‐derived mesenchymal stromal cells on a nano‐scale modified titanium | |
| Yang et al. | Simvastatin-loaded porous implant surfaces stimulate preosteoblasts differentiation: an in vitro study | |
| Xu et al. | Long-term outcome of augmentation of the maxillary sinus using deproteinised bone particles experimental study in rabbits | |
| Carvas et al. | A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration | |
| Bergamo et al. | Osseointegration of implant surfaces in metabolic syndrome and type‐2 diabetes mellitus | |
| Qiu et al. | Copper‐deposited diatom‐biosilica enhanced osteogenic potential in periodontal ligament stem cells and rat cranium | |
| Berger et al. | Hydrophilic implants generated using a low-cost dielectric barrier discharge plasma device at the time of placement exhibit increased osseointegration in an animal pre-clinical study: An effect that is sex-dependent |